In addition, HHS Secretary Robert F. Kennedy Jr. addressed the delay in Novavax's approval in a CBS interview earlier this ...

The UK’s Voluntary Scheme for Branded Medicines Pricing and Access ( VPAG) was agreed upon by the ABPI, the research-based ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...

Valneva said it has been supplying Ixchiq to help the French government respond to a major outbreak of chikungunya in La ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular ...

The NEJM has fired back a response to the Department of Justice (DoJ) asserting its "commitment to evidence-based ...

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...

Anyone who purports to care about global health, about public health, should be speaking out against these actions, loudly ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat activated phosphoinositide ...

Despite being on the US market since 1989 – initially for medical uses like strabismus and blepharospasm, and later for ...

Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains ...